Logo image of ATAI

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

NASDAQ:ATAI - Nasdaq - NL0015000DX5 - Common Stock - Currency: USD

1.46  -0.07 (-4.58%)

After market: 1.45 -0.01 (-0.68%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ATAI. ATAI was compared to 198 industry peers in the Pharmaceuticals industry. ATAI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATAI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATAI has reported negative net income.
ATAI had a negative operating cash flow in the past year.
ATAI had negative earnings in each of the past 5 years.
In the past 5 years ATAI always reported negative operating cash flow.
ATAI Yearly Net Income VS EBIT VS OCF VS FCFATAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -65.11%, ATAI is doing worse than 67.68% of the companies in the same industry.
With a Return On Equity value of -88.25%, ATAI perfoms like the industry average, outperforming 43.43% of the companies in the same industry.
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ATAI Yearly ROA, ROE, ROICATAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATAI Yearly Profit, Operating, Gross MarginsATAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATAI has more shares outstanding than it did 1 year ago.
ATAI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ATAI is higher compared to a year ago.
ATAI Yearly Shares OutstandingATAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
ATAI Yearly Total Debt VS Total AssetsATAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -2.33, we must say that ATAI is in the distress zone and has some risk of bankruptcy.
ATAI's Altman-Z score of -2.33 is in line compared to the rest of the industry. ATAI outperforms 46.97% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that ATAI is not too dependend on debt financing.
ATAI has a Debt to Equity ratio (0.14) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACCN/A
WACC7.48%
ATAI Yearly LT Debt VS Equity VS FCFATAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.81 indicates that ATAI has no problem at all paying its short term obligations.
ATAI has a better Current ratio (5.81) than 74.75% of its industry peers.
ATAI has a Quick Ratio of 5.81. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.
ATAI's Quick ratio of 5.81 is fine compared to the rest of the industry. ATAI outperforms 74.75% of its industry peers.
Industry RankSector Rank
Current Ratio 5.81
Quick Ratio 5.81
ATAI Yearly Current Assets VS Current LiabilitesATAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ATAI have decreased strongly by -220.69% in the last year.
The Revenue has decreased by -1.91% in the past year.
The Revenue for ATAI have been decreasing by -75.28% on average. This is quite bad
EPS 1Y (TTM)-220.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%-127.78%

3.2 Future

ATAI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.92% yearly.
Based on estimates for the next years, ATAI will show a very strong growth in Revenue. The Revenue will grow by 289.89% on average per year.
EPS Next Y18.56%
EPS Next 2Y5.56%
EPS Next 3Y11.34%
EPS Next 5Y27.92%
Revenue Next Year-9.8%
Revenue Next 2Y-5.03%
Revenue Next 3Y421.48%
Revenue Next 5Y289.89%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ATAI Yearly Revenue VS EstimatesATAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ATAI Yearly EPS VS EstimatesATAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATAI. In the last year negative earnings were reported.
Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATAI Price Earnings VS Forward Price EarningsATAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATAI Per share dataATAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.56%
EPS Next 3Y11.34%

More info and screens

0

5. Dividend

5.1 Amount

ATAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (4/25/2025, 8:00:00 PM)

After market: 1.45 -0.01 (-0.68%)

1.46

-0.07 (-4.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-17 2025-03-17/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners27.75%
Inst Owner Change-0.22%
Ins Owners3.57%
Ins Owner Change28.14%
Market Cap289.53M
Analysts83.33
Price Target8.16 (458.9%)
Short Float %6.46%
Short Ratio4.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.67%
Min EPS beat(2)-115.21%
Max EPS beat(2)-0.12%
EPS beat(4)2
Avg EPS beat(4)-19.73%
Min EPS beat(4)-115.21%
Max EPS beat(4)27.97%
EPS beat(8)5
Avg EPS beat(8)15.76%
EPS beat(12)7
Avg EPS beat(12)-2.21%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.29%
PT rev (3m)14.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.57%
EPS NY rev (1m)-18.8%
EPS NY rev (3m)-18.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20%
Revenue NY rev (1m)100%
Revenue NY rev (3m)100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 874.72
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-0.93
EYN/A
EPS(NY)-0.76
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.11%
ROE -88.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.49%
Cap/Sales 7.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.81
Quick Ratio 5.81
Altman-Z -2.33
F-Score2
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-220.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y18.56%
EPS Next 2Y5.56%
EPS Next 3Y11.34%
EPS Next 5Y27.92%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%-127.78%
Revenue Next Year-9.8%
Revenue Next 2Y-5.03%
Revenue Next 3Y421.48%
Revenue Next 5Y289.89%
EBIT growth 1Y19.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.91%
EBIT Next 3Y-22.09%
EBIT Next 5Y1.57%
FCF growth 1Y14.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.57%
OCF growth 3YN/A
OCF growth 5YN/A